<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02598791</url>
  </required_header>
  <id_info>
    <org_study_id>GASOLIN sub 1</org_study_id>
    <nct_id>NCT02598791</nct_id>
  </id_info>
  <brief_title>GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake</brief_title>
  <acronym>GASOLIN</acronym>
  <official_title>GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Gentofte, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With the present study, the investigators aim to delineate the effects of GIP/GLP-1 receptor
      co-activity on food intake, appetite, bone health and fat metabolism in overweight/obese
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The gut-derived incretin glucagon-like peptide-1 (GLP-1) is a potent regulator of gastric
      emptying, appetite and food intake in humans whereas its sister incretin hormone,
      glucose-dependent insulinotropic polypeptide (GIP), does not seem to have independent effects
      on these variables in humans. Interestingly, recent data from rodents have shown that
      concomitant activation of the GIP and the GLP-1 receptor may potentiate the satiety-promoting
      and body weight-reducing effects of GLP-1. Also, evidence suggests that GIP may be an
      important mediator of bone remodelling and lipid deposition. The effect of simultaneous
      activation of the GIP and GLP-1 receptors on appetite, food intake, fat metabolism and bone
      health has not been thoroughly examined in humans. The aim of this study is to delineate the
      effects of GIP/GLP-1 receptor co-activation on food intake, mechanisms regulating food
      intake, fat and bone metabolism in obese subjects.

      Material and methods:

      The investigators plan to include 18 obese/overweight men without diabetes. The primary
      endpoint of the study is food intake during continuous intravenous infusions of saline
      (placebo), GIP, GLP-1 and GIP+GLP-1, respectively. Secondary endpoints includes resting
      energy expenditure (measured by indirect calorimetry), appetite, satiety and hunger
      assessments (measured by visual analogue scales), plasma insulin, C-peptide and glucagon
      secretion, plasma triglycerides, cholesterols, and free fatty acid responses and changes in
      plasma bone turnover markers.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Anticipated">June 20, 2018</completion_date>
  <primary_completion_date type="Actual">June 20, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>food intake</measure>
    <time_frame>250-280 min</time_frame>
    <description>How much does the participant eat of from the ad libitum meal, measured in gram</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hunger</measure>
    <time_frame>measured at time 0, 30, 60, 90, 120, 180, 210, 240 min</time_frame>
    <description>feeling of hunger measured on a visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>satiety</measure>
    <time_frame>measured at time 0, 30, 60, 90, 120, 180, 210, 240 min</time_frame>
    <description>feeling of satiety measured on a visual analogue scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resting energy expenditure (REE)</measure>
    <time_frame>-15 to 0 min. and 210 to 225 min.</time_frame>
    <description>changes in REE measured by a ventilated hood 15 minutes at baseline and 15 minutes at time point 210 min.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>-30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min</time_frame>
    <description>changes in insulin measured in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide level</measure>
    <time_frame>-30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min</time_frame>
    <description>changes in C-peptide level measured in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glucagon levels</measure>
    <time_frame>-30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min</time_frame>
    <description>changes in glucagon levels measured in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free fatty acid</measure>
    <time_frame>-30, 0, 30, 60, 90, 120, 180, 240 min</time_frame>
    <description>changes in free fatty acid measured in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin level</measure>
    <time_frame>-30, 0, 30, 60, 90, 120, 180, 240 min</time_frame>
    <description>changes in level of osteocalcin measured in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-terminal cross-linked telopeptide of bone collagen (CTX)</measure>
    <time_frame>-30, 0, 30, 60, 90, 120, 180, 240 min</time_frame>
    <description>changes in level of CTX measured in plasma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procollagen type 1 N-terminal propeptide (P1NP)</measure>
    <time_frame>-30, 0, 30, 60, 90, 120, 180, 240 min</time_frame>
    <description>changes in level of P1NP measured in plasma</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Obesity</condition>
  <condition>Adiposity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>GIP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 hour i.v. infusion of glucose-dependent insulinotropic polypeptide (4 pmol/kg/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 hour i.v. infusion of glucagon-like peptide-1 (1 pmol/kg/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NaCl (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 hour i.v. NaCl (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GIP + GLP-1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 hour co-infusion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GIP</intervention_name>
    <description>Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min)</description>
    <arm_group_label>GIP</arm_group_label>
    <arm_group_label>GIP + GLP-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GLP-1</intervention_name>
    <description>glucagon-like peptide-1 (1 pmol/kg/min)</description>
    <arm_group_label>GLP-1</arm_group_label>
    <arm_group_label>GIP + GLP-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NaCl (placebo)</intervention_name>
    <description>i.v. NaCl</description>
    <arm_group_label>NaCl (placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasian men

          -  Age between 25 and 70 years

          -  Body mass index (BMI) between 25 and 40 kg/m2

        Exclusion Criteria:

          -  Diabetes or prediabetes (defined as glycated haemoglobin (HbA1c) â‰¥ 43 mmol/mol)

          -  Anaemia (defined as haemoglobin &lt; 8.3 mmol/l)

          -  Any gastrointestinal disease that may interfere with the endpoint variables

          -  Anorexia, bulimia or binge eating disorder

          -  Allergy or intolerance to ingredients included in the standardised meals

          -  Tobacco smoking

          -  Any regular drug treatment that cannot be discontinued for minimum 18 hours

          -  Any physical or psychological condition that the investigator feels would interfere
             with trial participation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natasha C Bergmann, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Diabetesresearch, Gentofte Hospital, University of Copenhagen, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Diabetesresearch, Gentofte hospital</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Finan B, Ma T, Ottaway N, MÃ¼ller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruemmer D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gidda J, Vignati L, Zhang L, Hauptman JB, Lau M, Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde-Knape K, Konkar A, DiMarchi RD, TschÃ¶p MH. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013 Oct 30;5(209):209ra151. doi: 10.1126/scitranslmed.3007218.</citation>
    <PMID>24174327</PMID>
  </reference>
  <reference>
    <citation>Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013 Jun 4;17(6):819-37. doi: 10.1016/j.cmet.2013.04.008. Epub 2013 May 16. Review.</citation>
    <PMID>23684623</PMID>
  </reference>
  <reference>
    <citation>Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 Feb 1;101(3):515-20.</citation>
    <PMID>9449682</PMID>
  </reference>
  <reference>
    <citation>Nissen A, Christensen M, Knop FK, VilsbÃ¸ll T, Holst JJ, Hartmann B. Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J Clin Endocrinol Metab. 2014 Nov;99(11):E2325-9. doi: 10.1210/jc.2014-2547. Epub 2014 Aug 21.</citation>
    <PMID>25144635</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2015</study_first_submitted>
  <study_first_submitted_qc>November 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2015</study_first_posted>
  <last_update_submitted>October 20, 2017</last_update_submitted>
  <last_update_submitted_qc>October 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Gentofte, Copenhagen</investigator_affiliation>
    <investigator_full_name>Natasha Chidekel Bergmann</investigator_full_name>
    <investigator_title>MD Ph.D student</investigator_title>
  </responsible_party>
  <keyword>incretin hormones</keyword>
  <keyword>GIP</keyword>
  <keyword>GLP-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

